Skip to main content

Advertisement

Table 4 Arm C (vaccine + IL-2 + GM-CSF): patient profiles, clinical data, and immunological outcomes

From: The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Pt Age Cancer Stage on enrollment # of cycles Off-study reason PFS#(ms) OS* (ms) Immune response
Elispot
         Pre-vaccine Post-vaccine
1C 40 Rectal IV 15 PD 26.5 80.4 NA +
2C 59 Colon NED 14 Completed 110.2+ 110.2+ - -
3C 58 Lung III 1 PPS 8 72.8 ND
4C 35 Colon IV 6 PD 6.9 18.7 - -
5C 52 Rectal IV 3 PD 3.2 6.4 - -
6C 36 Rectal IV 2 PPS/Lost to follow-up 2+ 9.2 ND
7C 75 Colon IV 1 PD 0.9 5.2 ND
8C 49 Colon IV 3 PD 3.5 5.5 - -
9C 42 Colon IV 3 PD 4 7.6 - -
10C 48 Colon IV 2 PD 1.7 4.7 ND
11C 48 Rectal NED 15 Completed 120.4+ 120.4+ - +
12C 54 Colon IV 3 PD 3.6 26.6 + +
13C 57 Colon NED 3 PD 3.6 9.1 NA
14C 66 Pancreatic IV 2 PD 2.4 2.8 ND
15C 56 Rectal NED 4 PD 3.6 28.5 - +
16C 73 Pancreatic IV 3 PD 3.6 6.6 - -
17C 51 Colon IV 2 PD 1.9 7.9 ND
18C 57 Colon IV 3 PPS 4.4 9.8 - -
19C 66 Pancreatic IV 2 PD 2.1 2.7 ND
  1. #Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample no available. Immune response was marked as negative (-) or positive (+) as described in the manuscript.
  2. Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.